IL164897A0 - Fusions of cytokines and tumor targeting proteins - Google Patents

Fusions of cytokines and tumor targeting proteins

Info

Publication number
IL164897A0
IL164897A0 IL16489704A IL16489704A IL164897A0 IL 164897 A0 IL164897 A0 IL 164897A0 IL 16489704 A IL16489704 A IL 16489704A IL 16489704 A IL16489704 A IL 16489704A IL 164897 A0 IL164897 A0 IL 164897A0
Authority
IL
Israel
Prior art keywords
fusions
cytokines
tumor targeting
targeting proteins
proteins
Prior art date
Application number
IL16489704A
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of IL164897A0 publication Critical patent/IL164897A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL16489704A 2002-04-30 2004-10-28 Fusions of cytokines and tumor targeting proteins IL164897A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0209893.7A GB0209893D0 (en) 2002-04-30 2002-04-30 Conjugate
PCT/IB2003/002515 WO2003092737A1 (en) 2002-04-30 2003-04-30 Fusions of cytokines and tumor targeting proteins

Publications (1)

Publication Number Publication Date
IL164897A0 true IL164897A0 (en) 2005-12-18

Family

ID=9935814

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16489704A IL164897A0 (en) 2002-04-30 2004-10-28 Fusions of cytokines and tumor targeting proteins

Country Status (13)

Country Link
US (1) US20050074426A1 (xx)
EP (1) EP1499362A1 (xx)
JP (1) JP2005525115A (xx)
KR (1) KR20050003400A (xx)
CN (2) CN101433722A (xx)
AU (1) AU2003236969A1 (xx)
CA (1) CA2484425A1 (xx)
EA (2) EA200800386A1 (xx)
GB (1) GB0209893D0 (xx)
IL (1) IL164897A0 (xx)
NO (1) NO20045236L (xx)
WO (1) WO2003092737A1 (xx)
ZA (1) ZA200408768B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
US7109167B2 (en) 2000-06-02 2006-09-19 Bracco International B.V. Compounds for targeting endothelial cells, compositions containing the same and methods for their use
CA2594927A1 (en) * 2004-03-31 2005-10-13 Buck Institute Hunter-killer peptides and methods of use
AU2005317684B2 (en) 2004-12-23 2012-02-16 Molmed Spa Conjugation product
WO2006102395A2 (en) * 2005-03-22 2006-09-28 Medstar Health Inc Delivery systems and methods for diagnosing and treating cardiovascular diseases
CN102539734B (zh) * 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
PL1899364T3 (pl) 2005-05-17 2020-08-24 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
GB0708864D0 (en) * 2007-05-08 2007-06-13 Molmed Spa Cytokine Conjugate
CA2691075C (en) 2007-06-15 2017-04-11 Daniela Gast Treatment of tumors using specific anti-l1 antibody
NZ582330A (en) 2007-06-27 2012-05-25 Marinepolymer Tech Inc COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF
GB0803076D0 (en) * 2008-02-20 2008-03-26 Univ Ghent Mucosal Membrane Receptor and uses thereof
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
AU2009248105B2 (en) * 2008-05-13 2013-10-31 Molmed S.P.A. Conjugates for the treatment of mesothelioma
EP2448599A1 (en) * 2009-06-30 2012-05-09 Philogen S.p.A. Immunocytokines in combination with anti-erbb antibodies for the treatment of cancer
US9526251B2 (en) 2010-02-25 2016-12-27 Marrone Bio Innovations, Inc. Use of Burkholderia formulations, compositions and compounds to modulate crop yield and/or corn rootworm infestation
US8822193B2 (en) 2010-02-25 2014-09-02 Marrone Bio Innovations, Inc. Isolated bacterial strain of the genus Burkholderia and pesticidal metabolites therefrom
CN102260352B (zh) * 2010-05-28 2013-11-20 山东先声麦得津生物制药有限公司 靶向性白细胞介素融合蛋白及其制备方法与应用
WO2013158962A1 (en) * 2012-04-19 2013-10-24 The Board Of Trustees Of The Leland Stanford Junior University Imaging-aided gene therapy using mesenchymal stem cells as target-delivery vehicle
US9119401B2 (en) 2012-10-19 2015-09-01 Marrone Bio Innovations, Inc. Plant glutamine synthetase inhibitors and methods for their identification
CN104177500B (zh) * 2013-05-24 2018-05-25 江苏靶标生物医药研究所有限公司 一种肿瘤坏死因子相关凋亡配体融合蛋白及其制法和用途
US9914759B2 (en) * 2013-07-19 2018-03-13 Vib Vzw Targeted modified TNF family members
WO2016050702A1 (en) 2014-09-30 2016-04-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
GB201419184D0 (en) 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
CN112574316A (zh) * 2015-07-02 2021-03-30 博际生物医药科技(杭州)有限公司 用于肿瘤靶向治疗的白细胞介素-15融合蛋白
CN108135881B (zh) 2015-08-11 2020-11-13 同宜医药（苏州）有限公司 多配体药物偶联体及其用途
CN105218682B (zh) * 2015-10-26 2019-05-07 杨晶 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途
US10066023B2 (en) * 2015-10-30 2018-09-04 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
CN105585637B (zh) * 2015-12-23 2020-04-03 杨晶 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途
CN105622759A (zh) * 2016-01-04 2016-06-01 深圳精准医疗科技有限公司 IL-12/CD107a融合蛋白增强CTL抗肿瘤效果的治疗剂及其制法和用途
GB201602359D0 (en) * 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
EA201991204A1 (ru) 2016-12-22 2019-12-30 Университа Дельи Студи Манья Греча Катандзаро Моноклональное антитело против уникального сиалогликозилированного опухолеассоциированного эпитопа cd43
JP7246617B2 (ja) * 2017-02-01 2023-03-28 アクセルロン ファーマ インコーポレイテッド 免疫活性の増加における使用のためのＴＧＦβおよびＡＣＴＲＩＩアンタゴニスト
CN109467607B (zh) * 2017-12-28 2020-10-30 北京泽勤生物医药有限公司 一种靶向肿瘤的酸性敏感融合肽及其应用
CN108314741B (zh) * 2018-03-22 2021-08-03 中国人民解放军第四军医大学 一种肿瘤血管靶向抗癌肽nkl-dota及其制备方法
JP7460609B2 (ja) * 2018-05-14 2024-04-02 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン－２ポリペプチド及びその使用方法
WO2020006539A1 (en) * 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
CN108864251B (zh) * 2018-06-30 2022-06-14 大连理工大学 一类氨肽酶n激活的药物前体化合物及其制备方法和应用
CN117683140A (zh) * 2022-09-09 2024-03-12 北京昌平实验室 肿瘤靶向的以白介素2为活性成分的融合蛋白型药物前体

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US4988621A (en) * 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
US4879237A (en) * 1985-05-24 1989-11-07 La Jolla Cancer Research Foundation Use of peptides in control of cell attachment and detachment
US5547936A (en) * 1985-06-17 1996-08-20 La Jolla Cancer Research Foundation Inhibition of cell migration with synthetic peptides
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
DE3716513A1 (de) * 1987-05-16 1988-11-24 Basf Ag Proteine mit tnf-wirkung
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
EP0463080A4 (en) * 1989-03-15 1992-02-12 Mark L Tykocinsky Cd8-based pharmaceuticals
US5120829A (en) * 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
US5498694A (en) * 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
US5169930A (en) * 1990-01-05 1992-12-08 La Jolla Cancer Research Foundation Fibronectin receptor
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5648330A (en) * 1990-04-06 1997-07-15 La Jolla Cancer Research Foundation Method and composition for treating vascular graft occlusion
US5612311A (en) * 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5672585A (en) * 1990-04-06 1997-09-30 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5888814A (en) * 1994-06-06 1999-03-30 Chiron Corporation Recombinant host cells encoding TNF proteins
US5811388A (en) * 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
US6576239B1 (en) * 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
US6759509B1 (en) * 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6180084B1 (en) * 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
CN1239675A (zh) * 1998-06-23 1999-12-29 金斗植 抗肿瘤试剂
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
US7309694B2 (en) * 2000-02-15 2007-12-18 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
US7109303B2 (en) * 2000-02-15 2006-09-19 Fondazione Centro San Raffaele Del Monte Tabor Modified cytokines for use in cancer therapy
ATE526039T1 (de) * 2000-02-24 2011-10-15 Philogen Spa Zusammensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen
WO2001090326A2 (en) * 2000-05-22 2001-11-29 Pharmacia & Upjohn Company Novel matrix metalloproteinases
JP2004501664A (ja) * 2000-06-30 2004-01-22 ボード・オブ・リージェンツ，ザ・ユニヴァーシティ・オヴ・テキサス・システム 標的化薬剤送達のための腫瘍組織を浸潤する細胞特異的な内部移行ペプチドの単離
US20030077818A1 (en) * 2001-03-08 2003-04-24 Dickerson Erin B. Compositions and methods for targeting interleukin-12 to malignant endothelium
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands

Also Published As

Publication number Publication date
EA200800386A1 (ru) 2008-10-30
NO20045236L (no) 2005-01-31
JP2005525115A (ja) 2005-08-25
US20050074426A1 (en) 2005-04-07
CN100457189C (zh) 2009-02-04
KR20050003400A (ko) 2005-01-10
EA200401447A1 (ru) 2005-08-25
CN1665543A (zh) 2005-09-07
EA009955B1 (ru) 2008-04-28
AU2003236969A1 (en) 2003-11-17
WO2003092737A1 (en) 2003-11-13
ZA200408768B (en) 2007-03-28
EP1499362A1 (en) 2005-01-26
CN101433722A (zh) 2009-05-20
GB0209893D0 (en) 2002-06-05
CA2484425A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
IL164897A0 (en) Fusions of cytokines and tumor targeting proteins
EP1578450A4 (en) REINFORCEMENT OF BIOTIN-MEDIATED TARGETING
WO2003023008A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1576169A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME, AND METHODS OF USE THEREOF
AU2002353095A8 (en) Streptavidin expressed gene fusions and methods of use thereof
AU2002365202A8 (en) Synthetic genes for malarial proteins and methods of use
AU2003217956A8 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
EP1401858A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS COATING THEREOF AND METHOD OF USE
EP1432726A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS CODED FOR THEM, AND METHOD OF USE
EP1532238A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC ACIDS AND METHOD OF USE
WO2003040330A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
AU2003297399A8 (en) Nucleic acids encoding antifungal drug targets and methods of use
EP1549671A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC CAUSE, AND USE PROCESS
EP1399537A4 (en) THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING THEM, AND METHODS OF USE
AU2003258134A8 (en) Lung cancer target proteins and use thereof
AU2003304034A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1576168A4 (en) THERAPEUTIC POLYPEPTIDES, THESE CODING NUCLEIC ACIDS AND METHOD OF USE
AU2002365216A1 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
EP1577322A4 (en) NEW PROTEINS AND THEIR USE
AU2003270424A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
EP1589101A4 (en) NEW PROTEIN AND ITS GENE
AU2003267475A1 (en) Tumor targeting agents and uses thereof
AU2003222262A8 (en) Arrestin gene, polypeptide and methods of use thereof